Skip to content

Search

Showing results for "Study of bullying"

Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess

We conducted a systematic review of clinical trials and observational studies that address the utility of SXT for SSTI treatment, caused by either GAS or MRSA

FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil

Mapping murine genes controlling cutaneous leishmaniasis (CL) identified Fli1 as a candidate influencing resistance to L. major and enhanced wound healing.

Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial

Children in Papua New Guinea (PNG) are at high risk of pneumococcal infections. We investigated pneumococcal carriage rates, serotype distribution, and antimicrobial susceptibility in PNG children after vaccination with 10-valent or 13-valent pneumococcal conjugate vaccines (PCV10; PCV13).

The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized

Mucosal leishmaniasis (ML) follows localized cutaneous leishmaniasis (CL) caused by Leishmania braziliensis.

Old, painful rheumatic heart disease treatment could be phased out

An international trial reveals 95% of rheumatic heart disease patients prefer less painful penicillin injections under the skin, aiming to improve treatment adherence.

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India

Amphotericin B provides improved therapy for visceral leishmaniasis (VL) caused by Leishmania donovani

Fathers’ Commute to Work and Children’s Social and Emotional Well-Being in Germany

Is fathers’ commute to work associated with increases in child social and emotional well-being as measured in Strengths and Difficulties Questionnaires?

WA partnership to unlock new antibiotic weapon

The Kids Research Institute Australia and WA pharmaceuticals company Boulos and Cooper have signed a $685,000 agreement to develop what could be the first new class of antibiotics in decades.

Parent and Child Engagement in Family-oriented Therapies for Childhood Obesity

This project will be conducted in conjunction with the Perth Childrens Hospital Health Weight Service (PCHHWS) and will involve three phases.

Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community

We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community.